Anmeldung erfolgt in Kürze...
Details werden geladen...
Cellenkos, Inc.: Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHDHOUSTON, May
Ähnliche Seiten
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD) | The Manila Times
https://www.manilatimes.net/2026/05/05/tmt-newswire/pr-newswire/cellenkos-announces-fda-clearance-of-investigational-new-drug-ind-application-for-phase-1b-2a-trial-of-ck0802-in-steroid-refractory-graft-versus-host-disease-gvhd/2335494Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis | The ...
https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis/2305475
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma () | aktiencheck.de
https://www.aktiencheck.de/news/Artikel-Scancell_announces_FDA_clearance_of_IND_application_for_global_Phase_3_trial_of_iSCIB1_advanced_melanoma-19400545
Incyte : FDA Approves Jakafi XR In Myelofibrosis, Polycythemia Vera, And Graft-Versus-Host Disease | 02.05.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/incyte-fda-approves-jakafi-xr-in-myelofibrosis-polycythemia-vera-and-graft-versus-host-disease-1036097457
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis
https://www.finanznachrichten.de/nachrichten-2026-01/67524722-novaliq-receives-fda-ind-clearance-to-advance-nov05-in-a-phase-ii-clinical-trial-in-non-infectious-anterior-uveitis-004.htm